

1	Details of the person discharging managerial responsibilities	
a)	Name	<i>Michael Engsig</i>
b)	Position	<i>Chief Executive Officer</i>
2	Reason for notification	
a)	Initial notification/ Amendment	<i>Initial</i>
3	Details of issuer	
a)	Name	<i>Nykode Therapeutics ASA</i>
b)	LEI	<i>254900UKQHWYZJD22017</i>
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	<i>Shares in Nykode Therapeutics ASA (ISIN: NO0010714785)</i>
b)	Nature of the transaction	<i>Acquisition of shares</i>
c)	Price(s) and volume(s)	<p>Price(s) NOK 16.71</p> <p>Volume 6,000</p>
d)	Aggregated information -Average price, aggregated volume and total amount	<p>Price NOK 16.71</p> <p>Volume 6,000</p> <p>Total amount NOK 100,260</p>
e)	Date of the transaction	<i>29.02.2024</i>
f)	Place of the transaction	<i>XOSL - Oslo Stock Exchange</i>